FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry, particularly to an anti-DR5 antibody or its functional fragment.
EFFECT: invention allows efficiently enhance the cytotoxic activity of the anti-DR5 antibody and induce apoptosis in cells.
4 cl, 53 dwg, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW ANTI-DR5 ANTIBODY | 2011 |
|
RU2590711C2 |
| HUMANISED ANTI-AXL ANTIBODIES | 2010 |
|
RU2571224C2 |
| ANTI-B7-H3-ANTIBODY | 2012 |
|
RU2668170C2 |
| ANTIBODY SELECTIVE TO APOPTOSIS INDUCING LIGAND RECEPTOR ASSOCIATED WITH TUMOR NECROSIS FACTOR, AND USES THEREOF | 2001 |
|
RU2298013C2 |
| ANTIBODY SELECTIVE TO RECEPTOR APOPTOSIS-INDUCING LIGAND AND ASSOCIATED WITH TUMOR NECROSIS FACTOR AND ITS USING | 2002 |
|
RU2313537C2 |
| Siglec-15 ANTIBODY | 2010 |
|
RU2539790C2 |
| COMBINATION OF ANTIBODY HAVING SELECTIVITY IN RELATES TO APOPTOSIS INDUCING LIGAND RECEPTOR ASSOCIATED WITH TUMOR NECROSIS FACTOR AND OTHER THERAPEUTIC AGENTS | 2002 |
|
RU2313368C2 |
| DR5 ANTIBODIES AND USE THEREOF | 2006 |
|
RU2458072C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF GALLBLADDER CANCER | 2013 |
|
RU2649802C2 |
| PHARMACEUTICAL COMPOSITION FOR LIVER CANCER TREATMENT AND/OR PREVENTION | 2013 |
|
RU2640245C2 |
